series-c-plus
Stage
1
Investors
About
Metavention develops the iRF Denervation System, a minimally invasive, one-time renal denervation device that uses radiofrequency energy to disrupt overactive sympathetic nerves associated with high blood pressure and metabolic diseases. The company is conducting clinical studies and its device is currently for investigational use under U.S. federal law.
Explore Metavention's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.